Intraoperative Hyperspectral Imaging to guide prostate cancer removal

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses ex-vivo hyperspectral imaging of the prostate specimen acquired before formalin fixation during radical prostatectomy. The goal is to see if hyperspectral data can help identify positive surgical margins more accurately and quickly than current methods. The approach aims to reduce residual cancer at the margin while avoiding disruption to the specimen and surgical workflow. Participation is limited to patients with localized prostate cancer undergoing RP and meeting size criteria for imaging. The study takes place at a single center in Geneva, led by Massimo Valerio.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological diagnosis (biopsy) of Pca
* Prostate volume \< 100 cm3 (measured on preoperative MRI) for a smooth acquisition with the hyperspectral device
* Capable of forming his own views

Exclusion Criteria:

* Unwilling to participate.
* Inability to follow study procedures, for example due to language problems, psychological disorders, dementia, etc.

Where it's running

• Hôpitaux Universitaires de Genève - Dept de Chirurgie - Service d'Urologie
  Geneva, Canton of Geneva, Switzerland Recruiting

Study contacts

• Principal investigator: Massimo Valerio — Hug
• Study coordinator: Vincent Benard, Resident
• Email: vincent.benard@hug.ch
• Phone: + 41 79 553 62 68

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Focal Micro-boost Radiotherapy for Localized Prostate Cancer

  This study tests whether adding a small, targeted boost to MRI-visible prostate lesions during moderately hypofractionated radiotherapy can improve cancer control in men with localized intermediate- to high-risk prostate cancer.

  Recruiting Regina Elena Cancer Institute · Rome, Lazio · NCT07792993

• Sonablate HIFU Registry for Prostate Cancer and BPH

  This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.

  Recruiting Sonablate · Indianapolis, Indiana · NCT07757490

• Water IV: See if Aquablation helps localized prostate cancer patients choose active surveillance

  This trial tests whether Aquablation therapy can be as safe and effective as choosing active surveillance for men with localized prostate cancer who are considering surveillance instead of immediate treatment.

  Recruiting at 12 sites PROCEPT BioRobotics · Chandler, Arizona and 27 other locations · NCT07650448

• Whole-gland prostate dose boost versus SBRT alone for PSMA-staged localized and locally advanced prostate cancer

  We will test whether adding a whole-gland radiation boost (with brachytherapy or a stereotactic boost) improves cancer control compared with SBRT alone in men whose prostate cancer is confined to the prostate on PSMA PET.

  Recruiting Phase 2/3 Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07426055

• Oxybutynin ER to help early urinary continence after robotic prostatectomy

  This trial will test whether taking a daily extended-release oxybutynin pill helps men regain urinary control sooner after robot-assisted prostate removal.

  Recruiting National Taiwan University Hospital · Taipei · NCT06966778

• Comparing adaptive SBRT to standard image-guided SBRT for localized prostate cancer

  This study is testing if a new type of targeted radiation therapy for prostate cancer can improve urinary health compared to the standard radiation treatment.

  Recruiting Phase 3 University Health Network, Toronto · Toronto, Ontario · NCT06825091

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.